Stock BODALCHEM BODAL CHEMICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bodal Chemicals Limited

Equities

BODALCHEM

INE338D01028

Market Closed - Bombay S.E.
Other stock markets
 11:00:48 10/05/2024 BST 		5-day change 1st Jan Change
72.55 INR +1.00% Intraday chart for Bodal Chemicals Limited -5.91% -12.40%
03-06 Bodal Chemicals Limited announced that it expects to receive INR 214 million in funding CI
02-13 Transcript : Bodal Chemicals Limited, Q3 2024 Earnings Call, Feb 13, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • With an expected P/E ratio at 120.92 and 19.61 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
BODAL CHEMICALS LIMITED Stock Bodal Chemicals Limited
-12.40% 109M -
ECOLAB INC. Stock Ecolab Inc.
+17.73% 66.69B
A-
GIVAUDAN SA Stock Givaudan SA
+16.33% 41.24B
B+
FUJIFILM HOLDINGS CORPORATION Stock Fujifilm Holdings Corporation
+18.68% 25.89B
A-
EMS-CHEMIE HOLDING AG Stock EMS-CHEMIE HOLDING AG
+12.78% 19.81B
C+
CELANESE CORPORATION Stock Celanese Corporation
+0.85% 17.48B
B+
POSCO FUTURE M CO., LTD. Stock Posco Future M Co., Ltd.
-21.87% 15.86B
A-
SYMRISE AG Stock Symrise AG
+2.32% 15.35B
B+
ALBEMARLE CORPORATION Stock Albemarle Corporation
-10.29% 15.23B
C+
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A. Stock Sociedad Química y Minera de Chile S.A.
-22.30% 13.36B
A-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. BODALCHEM Stock
  4. Ratings Bodal Chemicals Limited